Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial
Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial
复制标题
北美单剂量口服霍乱活疫苗 CVD 103-HgR 的安全性和免疫原性：随机、安慰剂对照、双盲交叉试验的结果
作者：
K. Kotloff;S. Wasserman;Sylvia A. O'DONNELL;G. Losonsky;Stanley J. Cryz;M. M. Levine
我们进行了一项双盲、安慰剂对照、随机交叉研究，以评估 94 名北美成年人单剂 5 x 10(8)-CFU 活口服重组霍乱疫苗 CVD 103-HgR 的安全性和免疫原性。该疫苗耐受性良好，无相关不良反应。尽管疫苗经粪便排泄极少，但 97% 的受试者表现出血清杀弧菌抗体，72% 的受试者出现抗毒素反应。
We conducted a double-blind, placebo-controlled, randomized crossover study to evaluate the safety and immunogenicity of a single 5 x 10(8)-CFU dose of live oral recombinant cholera vaccine CVD 103-HgR in 94 North American adults. The vaccine was well tolerated without associated adverse reactions. Despite minimal fecal excretion of vaccine, 97% of subjects exhibited serum vibriocidal antibody and 72% had antitoxin responses.
泰国士兵和平民CVD 103-HgR口服霍乱活疫苗不同免疫方案的安全性和免疫原性。
DOI：
10.1093/infdis/165.6.1042
发表时间：
1992
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Su-Arehawaratana,P;Singharaj,P;Taylor,DN;Hoge,C;Trofa,A;Kuvanont,K;Migasena,S;Pitisuttitham,P;Lim,YL;Losonsky,G
通讯作者：
Losonsky,G